2e,6e-farnesol is a lipid of Prenol Lipids (PR) class. 2e,6e-farnesol is associated with abnormalities such as Granulomatous Disease, Chronic, pathologic fistula and Cavitation. The involved functions are known as Regulation, Metabolic Inhibition, cholesterol biosynthetic process, Process and Transcription, Genetic. 2e,6e-farnesol often locates in Plasma membrane, Cytoplasmic matrix, cornified envelope, Epidermis and peroxisome. The associated genes with 2E,6E-farnesol are RAB3A gene, FOSL1 gene, CASP8AP2 gene, RCC1 gene and GALE gene. The related lipids are Sterols, Membrane Lipids and Steroids.
To understand associated biological information of 2E,6E-farnesol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
2E,6E-farnesol is suspected in Granulomatous Disease, Chronic, pathologic fistula and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with 2E,6E-farnesol
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Corsini A et al. | Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. | 1993 | Atherosclerosis | pmid:8216498 |
Giricz Z et al. | Role of cholesterol-enriched diet and the mevalonate pathway in cardiac nitric oxide synthesis. | 2003 | Basic Res. Cardiol. | pmid:12955403 |
George-Nascimento C et al. | Non enzymic formation of nerolidol from farnesyl pyrophosphate in the presence of bivalent cations. | 1971 | Biochem. Biophys. Res. Commun. | pmid:4334520 |
András IE et al. | Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells. | 2012 | Biochem. Biophys. Res. Commun. | pmid:22490665 |
Westfall D et al. | Metabolism of farnesol: phosphorylation of farnesol by rat liver microsomal and peroxisomal fractions. | 1997 | Biochem. Biophys. Res. Commun. | pmid:9015362 |
Miquel K et al. | Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells. | 1996 | Biochem. Biophys. Res. Commun. | pmid:8780704 |
Krishna G et al. | An enzyme-bound intermediate in the conversion of farnesyl pyrophosphate to squalene. | 1964 | Biochem. Biophys. Res. Commun. | pmid:4284347 |
Flach J et al. | The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10733934 |
Akopyan TN et al. | Proteolytic processing of farnesylated peptides: assay and partial purification from pig brain membranes of an endopeptidase which has the characteristics of E.C. 3.4.24.15. | 1994 | Biochem. Biophys. Res. Commun. | pmid:8297391 |
Fliesler SJ and Keller RK | Metabolism of [3H]farnesol to cholesterol and cholesterogenic intermediates in the living rat eye. | 1995 | Biochem. Biophys. Res. Commun. | pmid:7763243 |